Evidence map›Paper›PMID 40500301›Full record

ArticleNPJ Parkinson's disease2025

Lipid profiling of Parkinson's disease brain highlights disruption in Lysophosphatidylcholines, and triacylglycerol metabolism.

Ali Yilmaz, Nadia Ashrafi, Romana Ashrafi, Sumeyya Akyol, Nazia Saiyed, Ieva Kerševičiūtė, Migle Gabrielaite, Juozas Gordevicius, Stewart F Graham

Abstract read
In one paragraph

Article in NPJ Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Cellular and systemic modifiers of alpha-synuclein proteostasis.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2026
    Review
  2. Brain Sphingolipid and Phospholipid Levels Are Altered in XK Disease.Movement disorders : official journal of the Movement Disorder Society · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ali YilmazMetabolomics Department, Corewell Health Research Institute, Royal Oak, MI, USA.
Nadia AshrafiMetabolomics Department, Corewell Health Research Institute, Royal Oak, MI, USA.
Romana AshrafiMetabolomics Department, Corewell Health Research Institute, Royal Oak, MI, USA.
Sumeyya AkyolMetabolomics Department, Corewell Health Research Institute, Royal Oak, MI, USA.
Nazia SaiyedMetabolomics Department, Corewell Health Research Institute, Royal Oak, MI, USA.
Ieva KerševičiūtėVUGENE E 625 Kenmoor Avenue Southeast, Suite 301, Grand Rapids, MI, USA.
Migle GabrielaiteVUGENE E 625 Kenmoor Avenue Southeast, Suite 301, Grand Rapids, MI, USA.
Juozas GordeviciusVUGENE E 625 Kenmoor Avenue Southeast, Suite 301, Grand Rapids, MI, USA.
Stewart F GrahamMetabolomics Department, Corewell Health Research Institute, Royal Oak, MI, USA. stewart.graham@beaumont.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disorder following Alzheimer's disease, with a 1.5 times higher prevalence in males. Several lipid-related genetic risk factors for PD have been identified, and the brain lipid signature of PD patients is distinguishable from controls. To elucidate the molecular mechanisms underlying PD and its sex differences, we conducted a lipidomic analysis of postmortem brain samples from the primary motor cortex (Brodmann area 4) of 40 PD patients and 43 age- and sex-matched matched controls. Mass spectrometry based lipidomics analysis revealed notable differences in 95 lipid species, especially Triacylglycerols and Lysophosphatidylcholines. Notably, sex-stratified analysis suggested that mitochondrial dysfunction may explain the higher prevalence of PD in males. These findings highlight lipid dysregulation in PD and point to potential biomarkers for diagnosis, warranting further validation.

Identifiers

PMID40500301
PMCPMC12159154

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.